Search Results - "Aroda, V. R."

The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up by Aroda, V. R, Christophi, C. A, Edelstein, S. L, Zhang, P, Herman, W. H, Barrett-Connor, E, Delahanty, L. M, Montez, M. G, Ackermann, R. T, Zhuo, X, Knowler, W. C, Ratner, R. E, for the Diabetes Prevention Program Research Group

“…Context: Gestational diabetes (GDM) confers a high risk of type 2 diabetes. In the Diabetes Prevention Program (DPP), intensive lifestyle (ILS) and metformin…”
Get full text

Steroid Sex Hormones, Sex Hormone–Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program by Mather, K. J, Kim, C, Christophi, C. A, Aroda, V. R, Knowler, W. C, Edelstein, S. E, Florez, J. C, Labrie, F, Kahn, S. E, Goldberg, R. B, Barrett-Connor, E

“…Context: Steroid sex hormones and SHBG may modify metabolism and diabetes risk, with implications for sex-specific diabetes risk and effects of prevention…”
Get full text

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials by Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., Mehta, R., Woo, V., Lingvay, I.

“…In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications…”
Get full text

Long-term effects of lifestyle and metformin interventions in DPP on bone density by Schwartz, A. V., Pan, Q., Aroda, V. R., Crandall, J. P., Kriska, A., Piromalli, C., Wallia, A., Temprosa, M., Florez, H.

“…Summary In the Diabetes Prevention Program Outcome Study (DPPOS), a cohort at high risk of diabetes, randomization to intensive lifestyle intervention or…”
Get full text

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS) by Perreault, L., Pan, Q., Aroda, V. R., Barrett‐Connor, E., Dabelea, D., Dagogo‐Jack, S., Hamman, R. F., Kahn, S. E., Mather, K. J., Knowler, W. C.

“…Aim Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow‐up, whereas nearly all the…”
Get full text

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes by Yale, J.-F., Aroda, V.R., Charbonnel, B., Sinclair, A.J, Trescoli, C., Cahn, A., Bigot, G., Merino-Trigo, A., Brulle-Wohlhueter, C., Bolli, G.B., Ritzel, R.

“…Older people with type 2 diabetes (T2DM) are at an increased risk of hypoglycaemia and its consequences. However, efficacy and safety data for basal insulin…”
Get full text

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study) by Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L. A., Raskin, P., Zacho, J., Andersen, T. H., Philis-Tsimikas, A.

“…Aim To evaluate the efficacy and safety of adding insulin degludec (IDeg) to treatment in patients with type 2 diabetes receiving liraglutide and metformin and…”
Get full text

Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus by Henry, R. R., Aroda, V. R., Mudaliar, S., Garvey, W. T., Chou, H. S., Jones, M. R.

“…Aim: Colesevelam lowers glucose and low‐density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. This study examined the mechanisms by…”
Get full text

N-Acetylcysteine Enhances Antibody-Dependent Cellular Cytotoxicity in Neutrophils and Mononuclear Cells from Healthy Adults and Human Immunodeficiency Virus-Infected Patients by Roberts, Robert L., Aroda, Vanita R., Ank, Bonnie J.

“…Patients with AIDS have decreased levels of the intracellular antioxidant, glutathione, in their circulating lymphocytes and plasma. N-acetylcysteine (NAC)…”
Get full text

Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes by Mudaliar, S, Chang, A.R, Aroda, V.R, Chao, E, Burke, P, Baxi, S, Griver, K.A, O'Connor, D.T, Henry, R.R

“…Objective: To evaluate the effects of intensive insulin therapy alone or with added pioglitazone on renal salt/water balance and body fluid compartment shifts…”
Get full text

Trends in initiation of GLP-1 RA in patients with type 2 diabetes during 2014–2019: a US database study by Kosiborod, M, Aroda, V R, Broe Honore, J, Husemoen, L L N, Jensen, A B, Matthiessen, K S, Lingvay, I

“…Abstract Background/Introduction Evidence of cardiovascular (CV) benefit of certain glucagon-like peptide 1 receptor agonists (GLP-1 RAs) from CV outcomes…”
Get full text

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale by Yassin, Sayf A, Aroda, Vanita R

“…Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial cardiometabolic disorder. Almost half of adults with diabetes fail to achieve their…”
Get full text

Glitazones and the management of insulin resistance: what they do and how might they be used by Einhorn, Daniel, Aroda, Vanita R, Henry, Robert R

“…Thiazolidinediones (glitazones) are the only compounds currently available that specifically target tissue insulin resistance. The two currently available…”
Get more information

A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis by Mahata, S K, Mahata, M, Yoo, S H, Taupenot, L, Wu, H, Aroda, V R, Livsey, C V, Taulane, J P, Goodman, M, Parmer, R J, O'Connor, D T

Get more information